logo
  

Trio-Tech International Q2 Earnings Stay Flat

Trio-Tech International (TRT), a service provider to the semiconductor industry, Monday reported stagnant earnings for the second quarter, while revenues decreased 2 percent.

Earnings remained unchanged at $507 thousand or $0.12 per share from over a year ago.

Revenues decreased to $12.20 million from $12.39 million in the prior year, on a decline in revenue of testing services segment.

In pre-market activity, Trio-Tech shares are trading at $5.17, up 1.57% on the New York Stock Exchange.

For comments and feedback contact: editorial@rttnews.com

Business News

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT